<div id="readability-page-1"><p>Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) insider Mittie Doyle sold 679 shares of the company's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $16.00, for a total transaction of $10,864.00. Following the completion of the transaction, the insider owned 3,622 shares in the company, valued at $57,952. This represents a 15.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.</p><p>Mittie Doyle also recently made the following trade(s): </p><ul><li>On Monday, March 16th, Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock. The shares were sold at an average price of $16.15, for a total transaction of $411,695.80. </li></ul><div><p><span></span><span>Get <strong>Avalo Therapeutics</strong> alerts:</span></p></div><h2>Avalo Therapeutics Stock Performance</h2><p>NASDAQ AVTX remained flat at $17.76 during midday trading on Friday. The company's stock had a trading volume of 1,109,141 shares, compared to its average volume of 845,897. Avalo Therapeutics, Inc. has a 1-year low of $3.39 and a 1-year high of $20.72. The firm has a 50 day simple moving average of $15.50 and a 200-day simple moving average of $15.91. The stock has a market capitalization of $404.75 million, a P/E ratio of -3.10 and a beta of 0.93. </p><p>Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last released its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $1.17. The firm had revenue of $0.06 million during the quarter, compared to analysts' expectations of ($0.21) million.  As a group, research analysts anticipate that  Avalo Therapeutics, Inc. will post -19.07 EPS for the current year. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of research analysts have issued reports on the company. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Avalo Therapeutics in a report on Friday, January 9th. Mizuho raised shares of Avalo Therapeutics to a &#34;strong-buy&#34; rating in a report on Thursday, December 18th. BTIG Research  reaffirmed a &#34;buy&#34; rating and issued a $40.00 price objective on shares of Avalo Therapeutics in a report on Tuesday, March 24th. HC Wainwright upped their price objective on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, March 25th. Finally, Guggenheim started coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They set a &#34;buy&#34; rating and a $50.00 target price on the stock. One analyst  has rated the stock with a Strong Buy rating, five have given a Buy rating and one  has assigned  a Sell rating to the stock. According to MarketBeat, the company  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $42.25.</p><p><b>View Our Latest Research Report on Avalo Therapeutics</b></p><h2>Hedge Funds Weigh In On Avalo Therapeutics</h2><p>A number of institutional investors have recently bought and sold shares of AVTX. Caligan Partners LP acquired a new position in  Avalo Therapeutics in the 3rd quarter valued at about $10,592,000.  Balyasny Asset Management L.P. acquired a new position in  Avalo Therapeutics in the third quarter valued at approximately $10,390,000.  Vanguard Group Inc. grew its position in  Avalo Therapeutics by 314.9% in the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company's stock worth $8,803,000 after acquiring an additional 525,696 shares during the period.  Millennium Management LLC grew its position in  Avalo Therapeutics by 380.2% in the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company's stock worth $11,985,000 after acquiring an additional 522,548 shares during the period.  Finally, Jennison Associates LLC acquired a new stake in  Avalo Therapeutics during the fourth quarter worth $8,637,000. 87.06% of the stock is owned by hedge funds and other institutional investors. </p><h2>About Avalo Therapeutics</h2> (Get Free Report)<p>Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.  </p><p>Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.</p><h2>See Also</h2><ul><li>Five stocks we like better than Avalo Therapeutics</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Avalo Therapeutics Right Now?</h2><p>Before you consider Avalo Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.</p><p>While Avalo Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AVTX

BMED

<p>Avalo Therapeutics insider Mittie Doyle sold 679 shares at $16.00 each, totaling $10,864, reducing her stake by 15.79% to 3,622 shares valued at approximately $57,952. The sale was part of a pre-arranged trading plan and disclosed to the SEC. Avalo's stock remained flat at $17.76, with a market cap of $404.75 million. Analysts have mixed ratings, with a consensus of "Moderate Buy" and an average price target of $42.25. Institutional investors hold 87.06% of the stock, reflecting strong interest in the company.</p>

Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 679 Shares